Table 1.
Clinical data for patients
Not Transplanted (n = 25) | Transplanted (n = 25) | P | |
---|---|---|---|
Age | 52.7 (±10.4) | 45.9 (±14.4) | 0.06 |
Male | 15 (62.5) | 20 (80) | 0.18 |
Diabetes mellitus | 4 (16) | 5 (20) | 0.11 |
Past history IHD | 6 (24) | 4 (16) | 0.48 |
Hypertension | 24 (96) | 22 (88) | 0.29 |
Heart failure | 3 (12) | 1 (4) | 0.29 |
Smoking status | |||
Never | 8 (32) | 16 (64) | |
Yes | 11 (44) | 6 (24) | 0.08 |
Ex | 6 (24) | 3 (12) | |
No. on hemodialysis | 12 (48) | 10 (44) | 0.41 |
Time on RRT before CMR1 (yr) | 2.31 (±2.6) | 3.01 (±3.0) | 0.47 |
Drug history | |||
ESA | |||
CMR1 | 20 (80) | 18 (72) | 0.51 |
CMR2 | 20 (80) | 1 (4) | <0.001 |
Beta blocker | |||
CMR1 | 8 (32) | 11 (44) | 0.38 |
CMR2 | 19 (76) | 15 (60) | |
Aspirin | |||
CMR1 | 6 (24) | 9 (36) | 0.36 |
CMR2 | 10 (40) | 9 (36) | 0.77 |
ACE-I/AIIRA | |||
CMR1 | 7 (28) | 6 (26) | 0.75 |
CMR2 | 8 (32) | 9 (36) | 0.77 |
Calcium channel antagonist | |||
CMR1 | 2 (8) | 7 (28) | 0.06 |
CMR2 | 4 (16) | 6 (24) | 0.48 |
Other clinical data | |||
Mean SBP | |||
CMR1 | 139 (±17.2) | 135 (±20.1) | 0.40 |
CMR2 | 145 (±20.5) | 147 (±17.4) | 0.31 |
Mean DBP | |||
CMR1 | 81 (±12.3) | 78 (±11.5) | 0.41 |
CMR2 | 77 (±13.2) | 81 (±13.1) | 0.35 |
Mean BSA (m2) | 1.86 (±0.19) | 1.88 (±0.19) | 0.80 |
Mean BMI (kg/m2) | |||
CMR1 | 26.4 (±4.0) | 26.1 (±5.2) | 0.79 |
CMR2 | 26.8 (±4.1) | 27.0 (±5.7) | 0.92 |
Mean hemoglobin (g/dl) | |||
CMR1 | 12.1 (±1.8) | 11.9 (±1.9) | 0.61 |
CMR2 | 13.0 (±7.0) | 12.8 (±2.3) | 0.89 |
Mean hematocrit | |||
CMR1 | 0.38 (±0.05) | 0.37 (±0.06) | 0.22 |
CMR2 | 0.37 (±0.05) | 0.39 (±0.06) | 0.26 |
Data are presented as number (%) or mean ± SD. Tests of significance are t test or χ2. IHD, ischemic heart disease; RRT, renal replacement therapy; ESA, erythropoiesis stimulating agent; CMR, cardiac MRI; ACE-I, angiotensin-converting enzyme inhibitor; AIIRA, angiotensin II receptor antagonist; SBP, systolic blood pressure (expressed in mmHg); DBP, diastolic blood pressure; BSA, body surface area; BMI, body mass index.